ABAlireza Bahiraee

Alireza Bahiraee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alireza Bahiraee has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Uncoupling of CSF biomarkers and clinical status in patients with a novel mutation of ATP13a2

    by Caspar Stephani, David Ewers, Daniela Stausberg, David Rasche, Alireza Bahiraee, Beschan Ahmad, M Bähr, Bryan Downie, Sina Hirschel, Silke Jeannette Pauli, et al.

    Summary: Cerebrospinal fluid (CSF) biomarkers are generally assumed to reflect the severity and progression of neurodegenerative disease. We report three siblings carrying a novel heterozygous ATP13A2 variant (p.Pro629Ser) who challenge this paradigm. Despite only slowly progressive cognitive decline, axonal neuropathy, and leukodystrophy on MRI, all established CSF markers of neuronal destruction were profoundly abnormal, with tau and phosphorylated tau levels exceeding even those seen in Alzheimer’s disease or Creutzfeldt– Jakob disease. Patient fibroblasts revealed lysosomal alterations and abnormal amyloid precursor protein processing, and CSF polyamine levels were strongly reduced, consistent with impaired ATP13A2 function. These cases define a new ATP13A2-associated phenotype and, most importantly, demonstrate a striking dissociation between biomarker profiles and clinical course, questioning the general validity of CSF markers as direct indicators of disease severity.

  • Study of the relationship between endothelial lipase gene polymorphism and serum levels of HDL-C, Apo A-I and severity of stenosis in non-diabetic coronary artery disease patients

    by Zohre Afshoon, Alireza Bahiraee, Fataneh Esmaeili, Elaheh Mansouri, Mohammad Amin Emami, Maryam Montaseri, Nahid Davoodian, Reyhane Ebrahimi, Ebrahim Eftekhar


  • Association analysis of premature coronary artery disease and cytochrome P450 2D6 (CYP2D6) C100T and G1846A genetic variants and haplotypes in Iranian population

    by Alireza Bahiraee, Azim Nejatizadeh, Hossein Farshidi, Keyanoosh Malekzadeh, Solaleh Emamgholipour, Reyhane Ebrahimi, Amirsaeed Sabeti Aghabozorgi, Mahdy Yazdany, Mohammad Shekari


  • Acetylation and insulin resistance: a focus on metabolic and mitogenic cascades of insulin signaling

    by Solaleh Emamgholipour, Reyhane Ebrahimi, Alireza Bahiraee, Farshad Niazpour, Reza Meshkani

    Insulin resistance is associated with an increased risk of several metabolic disorders including type 2 diabetes, hypertension and cardiovascular diseases. Advances over the last decade have expanded our understanding of the molecular mechanisms underlying insulin resistance; however, many details of the mechanisms causing insulin resistance remain unknown. Recently, attention has shifted toward the role of epigenetics in insulin resistance. In this regard, acetylation of the histone tails has been widely investigated for its role in influencing both metabolic and mitogenic cascades of insulin signaling. More specifically, histone acetyltransferases and histone deacetylases, as major modulators of chromatin accessibility and gene expression, have been studied to determine a possible interconnectivity between the special effects of lysine acetylation status and tyrosine phosphorylation networks on the target proteins of downstream pathways involved in both metabolic and mitogenic cascades of insulin signaling. There is accumulating evidence for the post-translational modification effects of IGFR, InsR, IRS1/2, PI3K, Akt, GLUT4, FoxO, PGC-1α, PPAR, AMPK and MAPKs on insulin resistance and glucose homeostasis. In this paper, we review the importance of acetylation of these factors in the regulation of insulin signaling and glucose metabolism, with a primary focus on the target proteins of downstream signaling of insulin. We also provide an update on the interplay between epigenetic modification and the cellular genome in the context of insulin signaling and describe the possible effect of the environment on this epigenetic regulation.


  • Circulating exosomal miRNAs in cardiovascular disease pathogenesis: New emerging hopes

    by Amirsaeed S. Aghabozorgi, Najmeh Ahangari, Tasnim E. Eftekhaari, Paria N. Torbati, Alireza Bahiraee, Reyhane Ebrahimi, Alireza Pasdar

    Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortality. Standard therapies have failed to significantly increase patients’ survival. Moreover, the majority of conventional screening procedures are ineffective for the diagnosis of CVDs at early stages. Accumulating evidence suggests that numerous cell types release a class of nano‐sized vesicles named exosomes into the extracellular space. Exosomes are widely distributed in various body fluids and contain a number of diverse biomolecules such as proteins, lipids, and both mRNA and noncoding RNAs which reflect host‐cell molecular architecture. MicroRNAs (miRNAs), which can be found in exosomes, could be taken up by both neighboring and distal cells. Not only has recent evidence indicated the regulatory role of exosomal miRNAs in the pathogenesis of CVD, but it has also been shown that differential expression of exosomal miRNAs in CVDs has made them promising biomarkers for early detection of CVDs. Owing to these remarkable features, exosomal miRNAs have emerged as hot spots in research. This review summarizes the role of exosomal miRNAs in the pathogenesis of CVDs and discusses their potential application in the clinical setting as both therapeutic and diagnostic tools.


  • The role of inflammation and its related microRNAs in breast cancer: A narrative review

    by Alireza Bahiraee, Reyhane Ebrahimi, Raheleh Halabian, Amirsaeed Sabeti Aghabozorgi, Jafar Amani

    Breast cancer is recognized as the most common type of cancer among women with a high rate of mortality all over the world. Over the past years, growing attention has been regarded to realize more about the mechanisms underlying the disease process. It is revealed that the progression of breast cancer may be strongly linked to chronic inflammation owing to the role of inflammatory factors in genetic instability and subsequent cancer predisposition. Although the association between breast cancer and inflammatory pathways has been well‐defined now, only recent evidence pointed towards the inflammation‐related microRNAs (miRNAs) as potential biomarkers and therapeutic targets involved in the crosstalk of multiple pathways during breast cancer development. Moreover, the practical interactions between these miRNAs and inflammatory factors are also a little characterized. In this review, we intended to describe the effects of predominant inflammatory pathways such as cytokines, phosphoinositide 3‐kinase/protein kinase B, and nuclear factor kappa B in association with tumor promoting and tumor suppressing miRNAs on breast cancer progression. Providing new studies in the field of combining biomarkers for early diagnosis, prognosis, and monitoring breast cancer are very important. Notably, understanding the underlying mechanisms of miRNAs as a possible link between inflammation and tumorigenesis may offer a novel insight for combating this epidemic.